The Data Reality: Customer Experience Myths Debunked
Register Now
Secondary Hero Background Image

Takeda brings clinical data to life for AI

96%

of data moved to the cloud

40%

higher data productivity

Millions

saved in IT overhead

Stat Image

  • Cloud migration efficiency: Takeda moves 96% of its data to the cloud, increasing data productivity by 40% and saving millions in IT overhead through an optimized infrastructure with Informatica and AWS.
  • Unified data management: Using Informatica’s platform, Takeda establishes a centralized data hub, enhancing data quality and governance, crucial for speeding up clinical trials and AI readiness.
  • AI-powered innovation: By leveraging AI-ready strategies, Takeda accelerates drug development using Informatica CLAIRE® for robust data management, setting a strong foundation for future AI advancements in therapeutics.

Injecting AI efficiency into drug development

In the high-stakes world of life sciences innovation, the need for speed is constant—and data can make all the difference. Whether it’s identifying the right compounds for testing, or using predictive models to support more efficient trials, the world’s leading biopharmaceutical companies are tapping into the power of data and AI to speed up drug development.

Just ask Takeda, the Japan-based pioneer in life-transforming treatments dating back to 1781. “It’s a really exciting time in pharma, with AI and Generative AI coming onto the healthcare scene,” says Chief Data Officer Barbara Latulippe. “We all know clinical trials have a long development time. The more we can leverage data and technology, the faster we can get new therapies to our patients and drive positive change in their lives.”

Takeda is focused on the discovery and development of life-transforming treatments in core therapeutic and business areas, including gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Behind every breakthrough therapy is a complex web of actions, including R&D discovery, testing design, trial recruitment, data validation, and regulatory approvals—all of which generate vast amounts of data that must be managed effectively.

Latulippe’s prescription? A strong dose of data literacy, modernization and democratization. The goal was to fuel both a technical and cultural shift in how teams use data, supporting faster clinical innovation today, while laying a future-proof foundation for responsible, scalable AI.

“Every CDO needs to drive value with data, whether that’s simplification or acceleration in the ability to onboard data assets,” she says of her C-level mandate, spanning data, digital and technology. “As a biopharmaceutical company, we’re literally in the business of bringing data to life. To get therapies to our patients as quickly as possible, that means a focus on access, governance, quality and trust so our data is AI-ready.”

Developing a modern cloud data backbone

The first step in realizing this data-driven vision was modernization. Decades of organic and inorganic growth at Takeda had gradually created a large and fragmented data estate. Growing data volumes and myriad point solutions made it difficult to efficiently turn vast R&D datasets into breakthrough insights. There were also the immense IT overhead costs of a dozen on-premises data centers.

“With data volumes growing 20% each year, we needed the strategy of a cloud-first, AI-driven infrastructure as a service that can be optimized across the company,” says Latulippe of her new approach. “Modernizing our infrastructure in the cloud allows us to leverage greater performance and scalability. We can simplify our tech stack and improve the user experience while driving cost efficiencies.”

Takeda’s new data architecture would need to combine data lakes, warehouses and integration into a centralized, cloud-native layer.